Minimally Invasive Surgery Versus Open Radical Hysterectomy in Presumably Early Stage Cervical Cancer: a Retrospective Multicenter Non-inferiority Study Comparing Overall and Progression-free Survival.
NCT ID: NCT07120529
Last Updated: 2025-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2025-09-15
2030-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Eligible participants will include adult, legally competent women diagnosed with early-stage cervical cancer (FIGO stages IB1-IIA1, excluding FIGO IB3) with negative sentinel lymph node biopsy (SNB) confirmed by ultrastaging.
The main questions it aims to answer are:
Is there a difference in overall survival (OS) and progression-free survival (PFS) between laparoscopic and abdominal radical hysterectomy? Are postoperative complication rates and recurrence patterns comparable between the two surgical approaches?
Researchers will compare outcomes in patients undergoing radical laparoscopic hysterectomy versus abdominal hysterectomy to assess differences in survival, complications, and recurrence.
Participants will:
Have undergone radical hysterectomy (type B or C per Querleu-Morrow classification), preceded optionally by conization, with the use of uterine manipulators and absence of vaginal cuff protection explicitly excluded; Have had SNB as part of surgical staging; Be followed every 6 months for 5 years; Undergo clinical gynecologic examination and transvaginal and/or transabdominal ultrasound during follow-up; Undergo additional imaging (CT and/or pelvic MRI) in case of symptoms suggestive of recurrence.
All participants will follow standard post-treatment surveillance. No additional interventions beyond routine follow-up will be performed. Data on OS, PFS, complications (within 30 and 60 days postoperatively, classified by Clavien-Dindo), duration of surgery, recurrence site, and demographic characteristics will be collected.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Laparoscopic Approach to Cervical Cancer
NCT00614211
Prospective Study Assessing Emotional, Sexual and Quality of Life Concerns Of Women Undergoing Removal of the Cervix Versus Removal of the Uterus,Ovaries and Fallopian Tubes For Treatment Of Early Stage Cervical Cancer
NCT00579787
Laparoscopic vs Abdominal Radical Hysterectomy In Patients With Early Cervical Cancer
NCT01258413
Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer
NCT01658930
2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial
NCT02320578
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective of this study is to compare overall survival (OS) and progression-free survival (PFS) between the two surgical approaches. Secondary objectives include assessment of short-term surgical morbidity, recurrence patterns, and demographic and clinical factors potentially associated with adverse outcomes.
Study Population Eligible participants will be adult (≥18 years), legally competent women diagnosed with early-stage cervical cancer, defined as FIGO 2018 stages IB1 to IIA1, excluding IB3 tumors. All patients must have negative sentinel lymph node biopsy (SNB) results confirmed by ultrastaging.
To ensure homogeneity and minimize confounding associated with surgical technique, strict intraoperative criteria will be applied:
Use of a uterine manipulator is not permitted; A protective vaginal cuff closure maneuver (e.g., by suture, clamp, or stapler) must be performed to prevent tumor spillage during colpotomy; SNB may be performed as a first step, followed by radical hysterectomy classified as type B or C according to the Querleu-Morrow classification; Preoperative conization is allowed but not mandatory.
Study Design This is a retrospective cohort study with prospective follow-up. Surgical and perioperative data will be collected retrospectively from medical records. Eligible patients who underwent radical hysterectomy by either laparoscopic or abdominal approach in the post-LACC era will be identified and included.
Prospective follow-up will be conducted over a minimum period of 5 years, with evaluations scheduled at 6-month intervals.
Each follow-up visit will include:
Gynecological examination and transvaginal and/or transabdominal ultrasound; In symptomatic patients, additional imaging including contrast-enhanced CT scan of the chest, abdomen, and pelvis, and pelvic MRI as clinically indicated.
Endpoints
Primary endpoints:
Overall survival (OS): Time from radical hysterectomy to death from any cause. Progression-free survival (PFS): Time from radical hysterectomy to first documented recurrence or death.
Secondary endpoints:
Surgical complication rates within 30 and 60 days postoperatively, categorized using the Clavien-Dindo classification; Anatomic site and mode of recurrence (local, regional, or distant); Duration of surgery; Demographic and clinical variables, including age, BMI, tumor size, histologic subtype, and lymphovascular space invasion (LVSI).
Data Collection and Management Data will be extracted from patient medical records, surgical reports, pathology reports, and follow-up documentation. No study-specific interventions will be introduced beyond the standard follow-up protocol consistent with national and institutional guidelines for cervical cancer surveillance.
All clinical, surgical, and outcome data will be anonymized and stored securely. Data analysis will involve time-to-event methods (Kaplan-Meier curves, Cox proportional hazards models) and comparative statistics (e.g., chi-square, t-test, or non-parametric equivalents as appropriate).
Scientific Rationale The LACC trial demonstrated inferior disease-free and overall survival outcomes for minimally invasive radical hysterectomy compared to open surgery, which prompted a global shift in surgical practice. However, methodological concerns-including inconsistent use of uterine manipulators, absence of protective colpotomy techniques, and variability in surgeon experience-may have influenced the observed outcomes.
This study seeks to investigate whether meticulous surgical technique, standardized intraoperative precautions (such as omission of uterine manipulators and protective closure of the vaginal cuff), and proper patient selection (i.e., early-stage tumors with negative SNB) can mitigate the risks previously associated with the laparoscopic approach.
By comparing outcomes in a well-defined cohort treated after dissemination of the LACC trial results, this study aims to provide contemporary, real-world data on the oncologic safety of laparoscopic radical hysterectomy in selected early-stage cervical cancer patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RLH
Radical laparoscopic hysterectomy
CT scan
CT chest, abdominal, pelvis during follow-up
Ultrasound scan (Transvaginal or Transabdominal)
Transvaginal and transabdominal ultrasound scan during follow-up
Gynecological examination
Gynecological standard examination during follow-up
RAL
Radical open hysterectomy
CT scan
CT chest, abdominal, pelvis during follow-up
Ultrasound scan (Transvaginal or Transabdominal)
Transvaginal and transabdominal ultrasound scan during follow-up
Gynecological examination
Gynecological standard examination during follow-up
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT scan
CT chest, abdominal, pelvis during follow-up
Ultrasound scan (Transvaginal or Transabdominal)
Transvaginal and transabdominal ultrasound scan during follow-up
Gynecological examination
Gynecological standard examination during follow-up
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
85 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Silesia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Krzysztof Nowosielski
Prof.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uniwersyteckie Centrum Onkologii, Uniwersytecki Szpital Kliniczny w Białymstoku
Bialystok, , Poland
Department of Gynaecology, Obstetrics and Gynaecological Oncology, University Clinical Centre, Medical University of Silesia
Katowice, , Poland
Klinika Ginekologii, Świętokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakład Opieki Zdrowotnej
Kielce, , Poland
Oddział Ginekologii Onkologicznej z Pododdziałem Urologii, Opolskie Centrum Onkologii
Opole, , Poland
Department of Gynaecological Oncology,
Wroclaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BNW/NWN/0052/KB/59/25
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.